AstraZeneca PLC (AZN.L)


LSE - LSE Delayed Price. Currency in GBp
5,099.00-71.00 (-1.37%)
At close: 12:05 PM EDT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open5,139.00
Prev Close5,170.00
Bid5,091.00 x 6100
Ask5,200.00 x 13000
Day's Range5,098.82 - 5,184.57
52wk Range3,680.00 - 5,505.00
1y Target EstN/A
Market Cap64.5B
P/E Ratio (ttm)29.14
BetaN/A
Volume2,059,779
Avg Vol (3m)2,741,863
Dividend & YieldN/A (N/A)
Earnings DateN/A
  • Benzinga5 hours ago

    vTv Therapeutics Shares Initiated With Buy Rating, $13 Target

    HC Wainwright has started coverage of vTv Therapeutics Inc (NASDAQ: VTVT ) with a Buy rating and $13 price target on the potential success of its three late-stage drugs, especially the two diabetic compounds. ...

  • Reuters13 hours ago

    Sanofi may win U.S. approval of $3 bln eczema drug by March

    French drugmaker Sanofi and its U.S. partner Regeneron Pharmaceuticals could win U.S. approval for their keenly awaited new eczema drug dupilumab, seen by analysts as a potential $3 billion-a-year seller, by next March. Sanofi badly needs new products to make up for flagging sales in its diabetes business, where its top-seller Lantus faces growing competition. The two companies said on Monday that the U.S. Food and Drug Administration had accepted dupilumab for priority review for treating atopic dermatitis (AD), a skin inflammation also known as atopic eczema, and set a target decision date of March 29.

  • Pharma Stock Roundup: Allergan Acquisitions in Focus, J&J to Buy Abbott's AMO
    Zacks3 days ago

    Pharma Stock Roundup: Allergan Acquisitions in Focus, J&J to Buy Abbott's AMO

    Allergan (AGN) remained in the limelight this week thanks to its NASH-focused acquisition deals.